Exo Therapeutics
9 known investors
Find your way into Exo Therapeutics
174 people in our graph share verified history with the Exo Therapeutics team — schools, employers, funds. One of them is your warm intro.
Anika Guptaunlockedknows David R. Liu · together at Broad Institute of MIT and Harvard (overlapped)
×7knows the team · via Broad Institute of MIT and Harvard
knows the team · via Harvard College
×2knows the team · via Beam Therapeutics
knows the team · via Howard Hughes Medical Institute
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
Founders & leadership
DL
David Liu, PhDFounder
AS
Alan Saghatelian, PhDCo-Founder
DL
David LiuinDavid Liu is a chemistry and genome editing researcher at Harvard University and the Broad Institute, as well as a Howard Hughes Medical Institute Investigator. He has founded or co-founded multiple biotechnology companies including Beam Therapeutics, Prime Medicine, Editas Medicine, and Exo Therapeutics, and has developed technologies including base editing and prime editing that are used in research and clinical applications.
AS
Alan Saghetelian
Investors · 9
Newpath Partners✓ verifiedBoston · $50K – $10M
CRV (Charles River Ventures)Bay Area · $250K – $5M
Nextech InvestZurich · $648K – $3.2M
Raptor GroupMiami Beachvia James J. Pallotta · inferred
Samsara BioCapitalPalo Alto
Biotechnology Value FundreportedSan Francisco
Casdin Capitalreported · 2 sourcesNew York
Novartis Venture FundreportedBasel · $5M – $25M
Also in the syndicate · 1
Morningside
Funding
SEC filings, press & company announcements$78M disclosed across 1 of 2 rounds · 2020–2021
- $78Mseries BOct 2021 · 3 sources
BVF Partners, Casdin Capital, Morningside, Nextech Invest, Samsara Biocapital
Source ↗ - Undisclosed amountSeries ADec 2020Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Founder mafia
2 people who came through Exo Therapeutics went on to found or lead other companies.
Competitors · 2
by search overlap
Exo Imaging23 shared keywordsExo is a company backed by leading venture capital and corporate investors focused on innovative technologies, with particular emphasis on healthcare, bioelectronic medicines, materials science, and deep technology solutions.
Lexeotx11 shared keywordsLexeo is a clinical-stage genetic medicine company developing gene therapies that target the genetic causes of cardiovascular diseases. Based in New York City, it focuses on treatments for heart health and other genetic diseases regardless of prevalence.
Companies competing with Exo Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Exo Therapeutics do?
- Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
- Who founded Exo Therapeutics?
- Exo Therapeutics was founded by David Liu, PhD, Alan Saghatelian, PhD, David Liu, Alan Saghetelian.
- Who are Exo Therapeutics's investors?
- Exo Therapeutics's investors include Newpath Partners, CRV (Charles River Ventures), Nextech Invest, Raptor Group, Samsara BioCapital, Biotechnology Value Fund, Casdin Capital, Novartis Venture Fund.
- How much funding has Exo Therapeutics raised?
- Exo Therapeutics has disclosed $78M raised across 1 of its 2 known rounds.